Table 6. Median time to recurrence (TTR) and the percentage of TTR less and more than 6 months after adjuvant oxaliplatin-based regimens between KRAS mutant and wild-type patients.

	Median time to recurrence		TTR less than 6 months after oxaliplatin-based regimens	TTR longer than 6 months after oxaliplatin-based regimens
KRAS mutant patients	11.4 mons (8.1–14.7)	P = 0.67	10/34 (29%)	24/34 (71%)	P = 0.53
KRAS wild-type patients	9.2 mons (7.0–11.4)		10/27 (37%)	17/27 (63%)